Bullish Signal: Jefferies Initiates 'Buy' on Sai Life Sciences; Rs 1300 Target
Analyzing: “Stock to buy: Jefferies lists 10 reasons to buy its top CRDMO pick Sai Life Sciences” by et_markets · 12 Mar 2026, 11:25 AM IST (about 2 months ago)
What happened
Jefferies has initiated 'Buy' coverage on Sai Life Sciences, a CRDMO company, setting a target price of Rs 1,300. This move is based on the company's 'follow-the-molecule' model, robust pipeline, global presence, and strong financial health, signaling confidence in its future growth trajectory.
Why it matters
Analyst initiations with 'Buy' ratings from prominent global brokerages like Jefferies often act as significant catalysts for stock prices. This endorsement not only validates Sai Life Sciences' business model but also draws broader investor attention to the Indian CRDMO sector, which is experiencing strong tailwinds from global pharmaceutical outsourcing.
Impact on Indian markets
Sai Life Sciences is expected to see immediate positive price action due to this strong recommendation. Other Indian CRDMO and CRAMS players like Divi's Laboratories (DIVISLAB), Laurus Labs (LAURUSLABS), and Syngene International (SYNGENE) could also experience a positive ripple effect, as the report highlights the attractive growth prospects of the entire sector.
What traders should watch next
Traders should monitor Sai Life Sciences' stock performance for sustained upward momentum and volume. Also, keep an eye on other CRDMO stocks for potential sector-wide re-rating. Any further positive analyst reports or new contract wins for these companies would be key confirmation signals.
Key Evidence
- •Jefferies initiated coverage on Sai Life Sciences with a 'Buy' rating.
- •Target price set at Rs 1,300.
- •Key investment drivers cited include integrated 'follow-the-molecule' model, healthy pipeline, global presence, and clean balance sheet.
- •Brokerage projects significant upside potential for the company.
Affected Stocks
Jefferies initiated 'Buy' coverage with a target price of Rs 1,300, citing strong growth outlook and integrated business model.
Positive sentiment for a peer in the CRDMO space could spill over, as it highlights the sector's growth potential.
As a prominent player in the CDMO/CRDMO segment, Laurus Labs could benefit from increased investor attention on the sector.
Another key player in the Indian CRDMO space, Syngene could see positive sentiment due to Jefferies' bullish view on a peer.
Sources and updates
AI-powered analysis by
Anadi Algo News